This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pseudoxanthoma elasticum, PXE탄력섬유성 거짓황색종

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q82.8 / Special Copayment Reduction: V314 / Re-certification cycle: 5 years
B. SynonymsNone
C. Adult onsetSkin findings appear in childhood–adolescence; vascular and ophthalmic complications become clinically prominent mainly in the 20s–40s
1. HistoryFirst described by Rigal in 1881; named PXE by Darier in 1896; ABCC6 gene identified in 2000
2. CausesABCC6 loss-of-function mutation → pyrophosphate deficiency → systemic calcification and fragmentation of elastic fibers and basement membranes
3. GeneticsAutosomal recessive (AR); ABCC6 gene (16p13.11); mostly truncating or the frequent p.Arg1141X mutation
4. General epidemiologyIncidence about 1/25,000–1/100,000; slightly higher diagnosis rate in females; worldwide distribution
5. PathophysiologyABCC6 deficiency → reduced hepatic pyrophosphate (PPi) secretion → systemic excess of inorganic phosphate → calcification of elastic fibers and vessel walls
6. SymptomsYellow skin papules and plaques, angioid streaks, macular degeneration, angina, peripheral arterial disease, gastrointestinal bleeding
7. SignsPlucked-chicken-skin yellow plaques on the neck and flexures, angioid streaks, Bruch's spots, asymmetric peripheral blood pressure, poorly palpable radial artery
8. ScreeningCarrier screening within the family; when clinically suspected, fundus examination, skin biopsy, radiologic assessment of calcification
9. DiagnosisConfirmed by skin biopsy (von Kossa/Alizarin Red staining + elastic fiber staining) + ABCC6 molecular genetic testing
10. TreatmentIntravitreal anti-VEGF injection (CNV treatment), management of cardiovascular risk factors, clinical trials of magnesium/pyrophosphate supplementation
11. PrognosisVision loss (macular degeneration) and cardiovascular complications are the main causes of morbidity; life expectancy may be shortened; large individual variation
12. PreventionGenetic counseling, prenatal diagnosis; early management of cardiovascular risk factors; regular ophthalmic follow-up; avoidance of contact sports and head trauma
13. ReferencesLeftthériot I et al. (2017) Pseudoxanthoma elasticum: A systemic metabolic disease and 9 other papers

1. History

Pseudoxanthoma elasticum (PXE) is a systemic hereditary connective tissue disease involving the skin, eyes, and cardiovascular system, characterized by pathological calcification and fragmentation of elastic fibers, blood vessels, and basement membranes. The disease name "pseudoxanthoma" was given to emphasize that, although the skin lesions clinically resemble xanthoma, the pathological mechanism is deposition of minerals such as calcium and phosphate rather than lipid accumulation.

The history of PXE begins in 1881, when the French physician Rigal first described a patient with peculiar yellow skin papules and plaques. Then in 1896, the French dermatologist Jean Darier named the disease "pseudoxanthome élastique" (pseudoxanthoma elasticum) and confirmed that degeneration of elastic fibers is the key histopathological finding. Later, Grönblad (1929) and Strandberg (1929) each reported the association between fundus angioid streaks and the skin lesions, and recognition of the association among these three findings gave rise to the alternative name "Grönblad-Strandberg syndrome."

During the 20th century, advances in electron microscopy and histochemical techniques confirmed the pathological calcification and fragmentation of elastic fibers, and vascular involvement was shown to be the cause of serious clinical complications. The decisive advance regarding the genetic cause came in 2000, when Bergen et al. and Le Saux et al. independently identified ABCC6 gene mutations as the cause of PXE. Subsequent studies confirmed that ABCC6 is an ATP-binding cassette transporter expressed mainly in the liver and involved in the secretion of inorganic pyrophosphate (PPi) into the circulation.

Since the 2000s, as understanding of the ABCC6–pyrophosphate–inorganic phosphate metabolic axis has deepened, PXE has been re-evaluated as a systemic metabolic disease rather than a simple skin and ophthalmic disease. Currently, the development of new treatment strategies using calcification-inhibiting substances such as magnesium and pyrophosphate is being actively researched.

2. Causes

The cause of pseudoxanthoma elasticum is systemic deficiency of inorganic pyrophosphate (PPi) due to loss-of-function mutations in the ABCC6 gene. ABCC6 (MRP6, multidrug resistance-associated protein 6) is an ATP-dependent membrane transporter (ABC transporter) highly expressed mainly in hepatocytes and proximal renal tubular cells.

The normal function of ABCC6 is to secrete ATP from the liver into the extracellular space, and the secreted ATP is hydrolyzed by the extracellular enzyme ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) to produce inorganic pyrophosphate (PPi) and AMP. PPi is a potent physiological calcification inhibitor that directly inhibits the growth of hydroxyapatite crystals. Therefore, when ABCC6 function is lost, the PPi concentration in circulating blood falls markedly, the calcification-inhibiting mechanism collapses, and pathological calcification progresses in tissues throughout the body.

Calcification appears mainly in elastic fibers, the tunica media of vessels, and basement membranes because these structures are sites that are vulnerable to calcium-phosphate binding even under normal conditions. In particular, elastic fibers of the mid-dermis, the retinal Bruch's membrane, and the media of peripheral arteries are involved from an early stage. Interestingly, ABCC6 itself is hardly expressed in the skin or eyes, so the pathological mechanism of PXE is understood not as a problem of skin or eye tissue itself but as a systemic metabolic abnormality due to deficiency of circulating pyrophosphate of hepatic origin.

In a small number of PXE patients, ENPP1 gene mutations rather than ABCC6 have been reported to produce a similar PXE phenotype (e.g., GACI type 2). In addition, the possibility of haploinsufficiency, with some mild clinical findings observed even in ABCC6 heterozygous carriers, has been raised, but most are asymptomatic.

3. Genetics

Pseudoxanthoma elasticum follows an autosomal recessive (AR) inheritance pattern. The causative gene is ABCC6, located on chromosome 16p13.11; it consists of 31 exons and encodes a protein of 1503 amino acids. ABCC6 has a typical ABC transporter structure with 12 transmembrane domains and 2 nucleotide-binding domains (NBDs).

To date, more than 400 pathogenic ABCC6 variants have been reported. The most common single mutation is p.Arg1141X (c.3421C>T) in exon 24, a frequent mutation found in about 30–40% of European PXE patients. This mutation is known to be located at a CpG hotspot and to occur repeatedly (recurrent mutation). The second most common mutation type is large exon deletions; deletions of the entire ABCC6 gene or some exons are observed in about 10–20% of patients.

Compound heterozygous mutations are found in many patients, with different pathogenic variants on each allele. Homozygous mutations are relatively more common in populations where consanguineous marriage is common. The genotype-phenotype correlation is not entirely clear, but some studies suggest that patients homozygous for truncating mutations tend to have a more severe clinical course. In contrast, compound heterozygotes for mild missense mutations are often clinically mild.

ABCC6 heterozygous carriers are mostly clinically asymptomatic, but there are reports that some may show mild PXE-like findings such as angioid streaks. The carrier frequency in the general population is estimated at about 1/100–1/160, which is consistent with the incidence of PXE. After identification of an index patient in the family, genetic counseling within the family is possible through carrier testing of both parents and testing of siblings.

4. General epidemiology

The incidence of pseudoxanthoma elasticum is reported to be about 1/25,000–1/100,000 births, with estimates varying somewhat among studies. It is distributed worldwide, and no significant differences in frequency among specific ethnic groups or regions have been reported, but carrier frequency may be relatively higher in populations of European descent owing to the high frequency of the p.Arg1141X mutation.

By sex, it occurs with equal frequency in males and females, but the diagnosis rate is slightly higher in females. This may be related to the tendency of women to respond more sensitively to changes in skin symptoms and seek care earlier, and is interpreted as not reflecting an actual sex difference in incidence.

Skin symptoms begin to appear in childhood–adolescence, but many patients are diagnosed only decades later with ophthalmic or cardiovascular complications, so the actual prevalence may be higher than reported figures. According to the US PXE-specialized registry (PXEi), there is known to be a delay of several years to decades, on average, until diagnosis.

There are case reports in Asian populations, including Korea, but epidemiological data are scarce compared with Western countries. In Korea, it can be partially identified through registration for the rare disease Special Copayment Reduction. The incidence may be somewhat higher in populations where consanguineous marriage is common, and familial clustering is sometimes observed.

5. Pathophysiology

The pathogenesis of pseudoxanthoma elasticum is explained by a stepwise mechanism of systemic inorganic pyrophosphate (PPi) deficiency → pathological soft tissue calcification due to loss of ABCC6 function. The ABCC6 protein is expressed mainly on the basolateral membrane of hepatocytes and functions to secrete ATP into the extracellular space. The secreted ATP is hydrolyzed by ENPP1 to produce AMP and PPi, and this PPi enters the circulation and acts as a systemic calcification inhibitor.

When ABCC6 function is lost, liver-derived ATP secretion decreases, and as a result the blood PPi concentration falls to 40–60% of normal. In a PPi-deficient environment, the mechanism inhibiting the growth of hydroxyapatite (Ca₅(PO₄)₃OH) crystals collapses, and calcium-phosphate complexes are abnormally deposited in soft-tissue elastic fibers, basement membranes, the vascular media, and elsewhere. This calcification process destroys the structural integrity of elastic fibers, causing fiber fragmentation and loss of function.

Calcification and fragmentation of the retinal Bruch's membrane induce choroidal neovascularization (CNV), which is the direct cause of exudative macular degeneration and vision loss. In the skin, yellow papules and plaques appear due to calcification and fragmentation of elastic fibers in the mid-dermis. Calcification of the medial elastic fibers and internal elastic lamina of medium-sized arteries causes arterial stiffness, reduced blood flow, and ischemic complications.

Because magnesium, like physiological PPi, has a mechanism that inhibits hydroxyapatite crystal growth, research is underway on whether magnesium supplementation can delay the progression of calcification in PXE. In addition, administration of exogenous PPi (bisphosphonates, etidronate, etc.) is being explored as a calcification-inhibiting strategy.

6. Symptoms

Pseudoxanthoma elasticum involves the skin, eyes, and cardiovascular system as its three main target organs, and symptoms of each organ appear independently or in combination.

Skin symptoms are usually the first findings to appear, occurring in childhood–adolescence. Small yellowish-white to yellow papules cluster in flexural areas such as the lateral neck, axillae, groin, antecubital fossae, and popliteal fossae, forming cobblestone or plucked-chicken-skin plaques. Thickening or sagging of the skin (laxity) also occurs. Skin symptoms are relatively mild, so patients sometimes do not recognize them much beyond a cosmetic concern.

Ophthalmic symptoms are the most important clinical problem. They are initially asymptomatic, but when choroidal neovascularization (CNV) forms due to calcification and rupture of the retinal Bruch's membrane, macular exudation, submacular hemorrhage, decreased visual acuity, metamorphopsia, central scotoma, and other symptoms appear. On fundus examination, angioid streaks radiating around the optic disc are characteristically observed. Without appropriate treatment, it often progresses to loss of central vision.

Cardiovascular symptoms include peripheral arterial disease (lower-limb claudication, coldness, reduced pulses), coronary artery disease (angina, myocardial infarction), cerebrovascular disease (TIA, stroke), and loss of peripheral pulses (especially the radial artery). Gastrointestinal bleeding occurs due to involvement of gastric mucosal vessels and is sometimes the first symptom of PXE. Obstetrically, the risk of delivery complications increases due to involvement of endometrial vessels during pregnancy.

7. Signs

The most characteristic finding on skin examination is yellow papules and plaques (cobblestone lesions) on the lateral neck or flexural areas. These lesions grossly resemble xanthomas but are distinguished histopathologically by deposition of calcium-phosphate complexes rather than lipid. Skin laxity (cutis laxa-like changes) may be observed at the sites of skin lesions, and yellow papules may rarely appear on the oral mucosa (lips, buccal mucosa).

On fundus examination, angioid streaks appear as reddish-brown lines radiating along the retinal vessels around the optic disc. These are cracks in Bruch's membrane through which the underlying choroidal pigment is seen. Mottled findings of Bruch's membrane (peau d'orange) are observed as pigmentary abnormalities in the perimacular region and may be a precursor of CNV formation. Macular exudation, hard exudates, submacular hemorrhage, and other findings are observed in advanced CNV.

On cardiovascular examination, reduced or absent peripheral pulses (especially the dorsalis pedis and radial arteries), asymmetry of blood pressure between limbs, and carotid or peripheral vascular bruits may be observed. The electrocardiogram may show ischemic changes. With involvement of abdominal vessels, abdominal discomfort and gastrointestinal bleeding (melena, hematemesis) may occur. A clinical picture of ischemic heart disease occurring at a young age is a clue to include PXE in the differential diagnosis.

8. Screening

Screening for pseudoxanthoma elasticum consists of diagnostic screening based on clinical suspicion and genetic screening based on family history. PXE should be clinically suspected in cases of macular degeneration at a young age, angioid streaks, or unexplained skin laxity and yellow lesions.

Fundoscopy is the most basic screening tool for identifying angioid streaks and Bruch's membrane abnormalities. Fluorescein angiography, optical coherence tomography (OCT), and OCT angiography (OCTA) are used for early detection of CNV and assessment of its activity.

Skin biopsy is performed on yellow papules or plaques and confirms calcification and fragmentation of elastic fibers in the mid-dermis. Calcium deposition is directly confirmed with von Kossa or Alizarin Red staining, and fiber fragmentation is assessed with elastic fiber stains (Verhoeff-van Gieson, orcein, etc.).

On radiologic examination, soft tissue calcification on plain X-ray or CT can be identified, and in particular peripheral arterial calcification and abdominal wall vascular calcification may be observed. After identification of an index patient in the family, ABCC6 molecular genetic testing is offered to family members for carrier screening. Prenatal screening, when there is a family history, is performed by ABCC6 genetic testing via CVS or amniocentesis.

9. Diagnosis

The diagnosis of pseudoxanthoma elasticum is confirmed by a combined approach of clinical findings + skin biopsy histopathology + fundus examination + ABCC6 molecular genetic testing. The revised diagnostic criteria proposed by Plomp et al. in 2010 are widely used.

Diagnostic criteria (2 major criteria + minor criteria):

On skin biopsy histopathology, thickening, fragmentation, and calcium deposition (von Kossa positive, Alizarin Red positive) of elastic fibers in the mid-dermis are characteristically observed. In particular, the finding of fibers breaking up or becoming granular due to deposition of calcium and phosphate in elastic fibers is diagnostic. Whereas elastic fibers in normal skin are smooth and continuous, in PXE skin they appear granular and as short, irregular fragments.

ABCC6 molecular genetic testing is performed by EB gene panel NGS or ABCC6 sequencing alone, and molecular confirmation is made when pathogenic variants are identified in both alleles. MLPA is performed in parallel to detect large deletions. When a variant is found in only one allele, diagnosis is possible if clinical criteria are met.

10. Treatment

No disease-modifying therapy has currently been established for pseudoxanthoma elasticum, and treatment focuses mainly on prevention and treatment of complications.

Ophthalmic treatment is the most important. For active choroidal neovascularization (CNV), intravitreal anti-VEGF injection (ranibizumab, bevacizumab, aflibercept, etc.) is used as standard treatment. Anti-VEGF therapy shows effects in PXE-related CNV similar to those in typical age-related macular degeneration and is effective in preserving vision when started early. Regular ophthalmic follow-up (every 6–12 months, more frequently when CNV is present) and self-monitoring (Amsler grid) are recommended.

Management of cardiovascular risk factors is essential for preventing cardiovascular complications. Risk factors such as hypertension, hyperlipidemia, diabetes, and smoking are actively controlled. The use of antiplatelet agents (aspirin, clopidogrel, etc.) should be decided by a balanced assessment of individual bleeding and thrombotic risk, and caution is needed when using antiplatelet agents in PXE patients at risk of gastrointestinal bleeding.

Magnesium supplementation is recommended based on the theoretical rationale that, like PPi, it can inhibit hydroxyapatite crystal growth and on some preclinical study results, but evidence from large clinical trials is still lacking. Clinical trials of PPi-like calcification inhibition using etidronate are underway. Gene therapy research aimed at correcting ABCC6 function is also being explored at the preclinical stage.

There is no specific treatment for skin lesions, but cosmetic plastic surgery may be performed in patients with severe skin laxity. Physical trauma to the head and eyes should be avoided, and in particular sports involving head impact (boxing, martial arts, etc.) that may promote rupture of Bruch's membrane are prohibited.

11. Prognosis

The prognosis of pseudoxanthoma elasticum varies greatly among individuals depending on the severity of clinical symptoms and whether complications occur. Overall, the disease rarely directly threatens life, but vision loss and cardiovascular complications are the main causes of morbidity and greatly affect quality of life and functional independence.

The ophthalmic prognosis is the most important. Angioid streaks appear in 70–80% of PXE patients, and when CNV develops among them, it often progresses to loss of central vision without treatment. With the introduction of anti-VEGF therapy, the rate of vision preservation has improved meaningfully, but repeated treatment is needed and long-term prognosis still varies greatly among individuals. CNV can develop in both eyes, so there is a risk of bilateral vision loss.

The cardiovascular prognosis varies with accompanying risk factors and disease severity. Some patients have relatively mild vascular involvement and maintain a near-normal lifespan without major complications, whereas others experience serious coronary or cerebrovascular disease in their 20s–30s. Gastrointestinal bleeding sometimes occurs at unexpected times and requires emergency treatment.

Skin symptoms themselves do not cause much functional impairment, but there is a psychosocial burden due to disfigurement. Pregnancy can increase the risk of CNV worsening and gastrointestinal bleeding, so thorough ophthalmic and obstetric follow-up is needed during pregnancy. Overall, PXE is a chronic disease with survival possible for decades after symptom onset, requiring ongoing multidisciplinary management.

12. Prevention

Prevention of pseudoxanthoma elasticum is divided into genetic counseling and prenatal/preimplantation diagnosis and prevention of complications in confirmed patients. Consultation with a genetics specialist should be offered to parents who have had an affected child (carrier parents) or to the patients themselves. Children of patients are carriers and generally have no clinical symptoms, so screening of the children is approached selectively.

In patients already diagnosed, regular ophthalmic follow-up (at least once a year when angioid streaks are present) and self-monitoring (Amsler grid) are important for prevention of ophthalmic complications. Avoiding eye trauma, prohibiting contact sports (boxing, wrestling, etc.), and avoiding head impact help prevent acute worsening of CNV due to rupture of Bruch's membrane.

For prevention of cardiovascular complications, no smoking, early detection and active treatment of hypertension, hyperlipidemia, and diabetes, regular aerobic exercise (but avoiding exercise that sharply raises blood pressure), limiting excessive calcium intake (caution with calcium supplements), and adequate magnesium intake are recommended. Dietary adjustment to increase intake of vitamin K2 (in its role as a calcification inhibitor) also has a theoretical rationale, but the level of evidence is still low.

Prenatal screening is performed, when both parents are carriers, by ABCC6 molecular genetic testing via CVS or amniocentesis. Preimplantation genetic diagnosis (PGD) may also be offered as an option. At diagnosis, patient education (disease characteristics, lifestyle adjustment, regular follow-up schedule, recognition of emergency symptoms) contributes importantly to long-term prognosis.

13. References

  1. Leftthériot I, Germain DP. Pseudoxanthoma elasticum: a systemic metabolic disease. Best Pract Res Clin Rheumatol. 2017;31(4):565-574. doi:10.1016/j.berh.2017.12.006
  2. Bergen AA, Plomp AS, Schuurman EJ, et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet. 2000;25(2):228-231. doi:10.1038/76109
  3. Le Saux O, Urban Z, Tschuch C, et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000;25(2):223-227. doi:10.1038/76102
  4. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA. 2000;97(11):6001-6006. doi:10.1073/pnas.100041697
  5. Plomp AS, Toonstra J, Bergen AA, van Dijk MR, de Jong PT. Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. Am J Med Genet A. 2010;152A(4):1049-1058. doi:10.1002/ajmg.a.33329
  6. Nitschke Y, Baujat G, Botschen U, et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012;90(1):25-39. doi:10.1016/j.ajhg.2011.11.020
  7. Vanakker OM, Martin L, Gheduzzi D, et al. Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol. 2007;127(3):581-587. doi:10.1038/sj.jid.5700610
  8. Georgalas I, Papaconstantinou D, Koutsandrea C, et al. Angioid streaks, clinical course, complications, and current therapeutic management. Ther Clin Risk Manag. 2009;5:81-89. doi:10.2147/tcrm.s3837
  9. Hendig D, Langmann T, Kocken S, et al. Gene expression profiling of ABC transporters in human macrophages and pseudoxanthoma elasticum fibroblasts. Lab Invest. 2007;87(6):611-621. doi:10.1038/labinvest.3700549
  10. Kranenburg G, de Jong PA, Mali WP, et al. Prevalence and risk factors for arterial calcifications in pseudoxanthoma elasticum. Orphanet J Rare Dis. 2019;14(1):35. doi:10.1186/s13023-019-1011-5